Complete financial analysis of Helius Medical Technologies, Inc. (HSDT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helius Medical Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Hammond Manufacturing Company Limited (HMM-A.TO) Income Statement Analysis – Financial Results
- Charlotte’s Web Holdings, Inc. (CWEB.TO) Income Statement Analysis – Financial Results
- Aena S.M.E., S.A. (ANYYY) Income Statement Analysis – Financial Results
- u-blox Holding AG (UBXN.SW) Income Statement Analysis – Financial Results
- Jiujiang Shanshui Technology Co.,Ltd (301190.SZ) Income Statement Analysis – Financial Results
Helius Medical Technologies, Inc. (HSDT)
About Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 644.00K | 787.00K | 522.00K | 661.00K | 1.50M | 478.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 583.00K | 463.00K | 298.00K | 388.00K | 846.00K | 0.00 | 0.00 | 0.00 | 171.78K | 0.00 | 0.00 |
| Gross Profit | 61.00K | 324.00K | 224.00K | 273.00K | 650.00K | 478.00K | 0.00 | 0.00 | -171.78K | 0.00 | 0.00 |
| Gross Profit Ratio | 9.47% | 41.17% | 42.91% | 41.30% | 43.45% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.94M | 4.26M | 5.99M | 4.58M | 8.06M | 9.94M | 14.39M | 4.72M | 3.83M | 171.78K | 4.25M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.21M | 8.47M | 5.65M | 4.26M | 895.50K | 4.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 774.40K | 0.00 | 0.00 |
| SG&A | 9.27M | 10.64M | 12.18M | 9.71M | 16.52M | 17.21M | 8.47M | 5.65M | 5.04M | 895.50K | 4.27M |
| Other Expenses | 276.00K | 181.00K | 200.00K | 363.00K | 64.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.49M | 15.08M | 18.37M | 14.66M | 24.65M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Cost & Expenses | 13.07M | 15.55M | 18.66M | 15.05M | 25.49M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Interest Income | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.00K | 20.07K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 1.95M | 5.17M | 1.67M | 176.49K | 0.00 | 0.00 |
| Depreciation & Amortization | 162.00K | 306.00K | 374.00K | 482.00K | 191.00K | 59.00K | 17.00K | 1.78M | 20.07K | 0.00 | 0.00 |
| EBITDA | -12.11M | -14.50M | -17.82M | -13.90M | -23.93M | -26.62M | -17.67M | -8.60M | -6.83M | -1.07M | -8.52M |
| EBITDA Ratio | -1,879.97% | -2,044.73% | -3,439.08% | -2,132.68% | -2,535.09% | -5,147.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.43M | -14.76M | -18.14M | -14.39M | -24.00M | -26.68M | -22.85M | -10.37M | -8.86M | -1.07M | -8.52M |
| Operating Income Ratio | -1,929.81% | -1,875.35% | -3,475.48% | -2,176.40% | -1,604.01% | -5,580.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.58M | 687.00K | 10.00K | 72.00K | 14.22M | -1.95M | -5.17M | -1.67M | 1.98M | 0.00 | 0.00 |
| Income Before Tax | -8.85M | -14.07M | -18.13M | -14.13M | -9.78M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | -8.52M |
| Income Before Tax Ratio | -1,374.22% | -1,788.06% | -3,473.56% | -2,137.67% | -653.81% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.51M | -10.00K | -193.00K | -14.12M | 3.96M | 10.34M | 1.67M | -146.62K | 0.00 | -8.52M |
| Net Income | -8.85M | -12.56M | -18.12M | -13.94M | 4.34M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | 0.00 |
| Net Income Ratio | -1,374.22% | -1,595.68% | -3,471.65% | -2,108.47% | 290.04% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| EPS Diluted | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential to generate neuroplasticity -- NEWTOWN, Pa., May 20,...
Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Michelle Bilski - Investor Relations-In-Site Communications Dane Andreeff - President and Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference...
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended...
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will...
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public...
Why Is Helius Medical Technology (HSDT) Stock Up 47% Today?
Helius Medical Technology (NASDAQ: HSDT ) stock is rocketing higher on Friday alongside heavy trading of the neurotechnology company's shares. This has more than 3.5 million shares of HSDT stock changing hands as of this writing.
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius' U.S. registrational program for Portable...
Helius Medical stock rallies 40%: explore why
Helius Medical Technologies Inc (NASDAQ: HSDT) is up close to 40% in premarket on Wednesday after teaming up with Lovell Government Services. Why is it good news for Helius Medical stock?
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024...
Source: https://incomestatements.info
Category: Stock Reports